The main risk is not product readiness but value capture. Palantir must convert intense AI interest into broad, durable production deployments before
hyperscalers, incumbent suites, and in-house builds narrow the workflow-governance gap. Regulatory scrutiny in healthcare and public sector can disrupt reference accounts, and the current valuation magnifies any pause in commercial conversion or government momentum.